Browse by Journal Title

2024

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs, M. and Jacob, A.S. and Kaul, H. and Kobe, C. and Kuhnert, G. and Pabst, T. and Greil, R. and Bröckelmann, P.J. and Topp, M.S. and Just, M. and Hertenstein, B. and Soekler, M. and Vogelhuber, M. and Zijlstra, J.M. and Keller, U.B. and Krause, S.W. and Dührsen, U. and Meissner, J. and Viardot, A. and Eich, H.T. and Baues, C. and Diehl, V. and Rosenwald, A. and Buehnen, I. and von Tresckow, B. and Dietlein, M. and Borchmann, P. and Engert, A. and Eichenauer, D.A.
Leukemia 38 (1): 160-167. January 2024

2023

Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
Briest, F. and Noerenberg, D. and Hennch, C. and Yoshida, K. and Hablesreiter, R. and Nimo, J. and Sasca, D. and Kirchner, M. and Mansouri, L. and Inoue, Y. and Wiegand, L. and Staiger, A.M. and Casadei, B. and Korkolopoulou, P. and Weiner, J. and Lopez-Guillermo, A. and Warth, A. and Schneider, T. and Nagy, Á. and Klapper, W. and Hummel, M. and Kanellis, G. and Anagnostopoulos, I. and Mertins, P. and Bullinger, L. and Rosenquist, R. and Vassilakopoulos, T.P. and Ott, G. and Ogawa, S. and Damm, F.
Leukemia 37 (11): 2237-2249. November 2023

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Jahn, E. and Saadati, M. and Fenaux, P. and Gobbi, M. and Roboz, G.J. and Bullinger, L. and Lutsik, P. and Riedel, A. and Plass, C. and Jahn, N. and Walter, C. and Holzmann, K. and Hao, Y. and Naim, S. and Schreck, N. and Krzykalla, J. and Benner, A. and Keer, H.N. and Azab, M. and Döhner, K. and Döhner, H.
Leukemia 37 (11): 2187-2196. November 2023

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.
Eifert, T. and Hsu, C.J. and Becker, A.L. and Graessle, S. and Horne, A. and Bemmann, F. and Zhang, Q. and Heuser, M. and Vasioukhin, V. and Scholl, S. and Hochhaus, A. and Siegerist, F. and Endlich, N. and Bullinger, L. and Lane, S.W. and Haas, S. and Schnoeder, T.M and Heidel, F.H.
Leukemia 37 (10): 2027-2035. October 2023

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.
Straube, J. and Eifert, T. and Vu, T. and Janardhanan, Y. and Haldar, R. and von Eyss, B. and Cooper, L. and Bruedigam, C. and Ling, V.Y. and Cooper, E. and Patch, A.M. and Bullinger, L. and Schnoeder, T.M. and Bywater, M. and Heidel, F.H. and Lane, S.W.
Leukemia 37 (4): 741-750. April 2023

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri, L. and Thorvaldsdottir, B. and Sutton, L.A. and Karakatsoulis, G. and Meggendorfer, M. and Parker, H. and Nadeu, F. and Brieghel, C. and Laidou, S. and Moia, R. and Rossi, D. and Catherwood, M. and Kotaskova, J. and Delgado, J. and Rodríguez-Vicente, A.E. and Benito, R. and Rigolin, G.M. and Bonfiglio, S. and Scarfo, L. and Mattsson, M. and Davis, Z. and Gogia, A. and Rani, L. and Baliakas, P. and Foroughi-Asl, H. and Jylhä, C. and Skaftason, A. and Rapado, I. and Miras, F. and Martinez-Lopez, J. and de la Serna, J. and Rivas, J.M.H. and Thornton, P. and Larráyoz, M.J. and Calasanz, M.J. and Fésüs, V. and Mátrai, Z. and Bödör, C. and Smedby, K.E. and Espinet, B. and Puiggros, A. and Gupta, R. and Bullinger, L. and Bosch, F. and Tazón-Vega, B. and Baran-Marszak, F. and Oscier, D. and Nguyen-Khac, F. and Zenz, T. and Terol, M.J. and Cuneo, A. and Hernández-Sánchez, M. and Pospisilova, S. and Mills, K. and Gaidano, G. and Niemann, C.U. and Campo, E. and Strefford, J.C. and Ghia, P. and Stamatopoulos, K. and Rosenquist, R.
Leukemia 37 (2): 339-347. February 2023

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
Ling, V.Y. and Straube, J. and Godfrey, W. and Haldar, R. and Janardhanan, Y. and Cooper, L. and Bruedigam, C. and Cooper, E. and Tavakoli Shirazi, P. and Jacquelin, S. and Tey, S.K. and Baell, J. and Huang, F. and Jin, J. and Zhao, Y. and Bullinger, L. and Bywater, M.J. and Lane, S.W.
Leukemia 37 (1): 143-153. January 2023

2022

Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.
Eichinger, A. and Poetschger, U. and Glogova, E. and Bader, P. and Basu, O. and Beier, R. and Burkhardt, B. and Classen, C.F. and Claviez, A. and Corbacioglu, S. and Deubzer, H.E. and Greil, J. and Gruhn, B. and Güngör, T. and Kafa, K. and Kühl, J.S. and Lang, P. and Lange, B.S. and Meisel, R. and Müller, I. and Sauer, M.G. and Schlegel, P.G. and Schulz, A. and Stachel, D. and Strahm, B. and Wawer, A. and Peters, C. and Albert, M.H.
Leukemia 36 (11): 2567-2576. November 2022

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn, N. and Jahn, E. and Saadati, M. and Bullinger, L. and Larson, R.A. and Ottone, T. and Amadori, S. and Prior, T.W. and Brandwein, J.M. and Appelbaum, F.R. and Medeiros, B.C. and Tallman, M.S. and Ehninger, G. and Heuser, M. and Ganser, A. and Pallaud, C. and Gathmann, I. and Krzykalla, J. and Benner, A. and Bloomfield, C.D. and Thiede, C. and Stone, R.M. and Döhner, H. and Döhner, K.
Leukemia 36 (9): 2218-2227. September 2022

The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.
Viñado, A.C. and Calvo, I.A. and Cenzano, I. and Olaverri, D. and Cocera, M. and San Martin-Uriz, P. and Romero, J.P. and Vilas-Zornoza, A. and Vera, L. and Gomez-Cebrian, N. and Puchades-Carrasco, L. and Lisi-Vega, L.E. and Apaolaza, I. and Valera, P. and Guruceaga, E. and Granero-Molto, F. and Ripalda-Cemborain, P. and Luck, T.J. and Bullinger, L. and Planes, F.J. and Rifon, J.J. and Méndez-Ferrer, S. and Yusuf, R.Z. and Pardo-Saganta, A. and Prosper, F. and Saez, B.
Leukemia 36 (8): 1969-1979. August 2022

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri, A.J.M. and Cwynarski, K. and Pulczynski, E. and Fox, C.P. and Schorb, E. and Celico, C. and Falautano, M. and Nonis, A. and La Rosée, P. and Binder, M. and Fabbri, A. and Ilariucci, F. and Krampera, M. and Roth, Al. and Hemmaway, C. and Johnson, P.W. and Linton, K.M. and Pukrop, T. and Gørløv, J.S. and Balzarotti, M. and Hess, G. and Keller, U. and Stilgenbauer, S. and Panse, J. and Tucci, A. and Orsucci, L. and Pisani, F. and Zanni, M. and Krause, S.W. and Schmoll, H.J. and Hertenstein, B. and Rummel, M. and Smith, J. and Thurner, L. and Cabras, G. and Pennese, E. and Ponzoni, M. and Deckert, M. and Politi, L.S. and Finke, J. and Ferranti, A. and Cozens, K. and Burger, E. and Ielmini, N. and Cavalli, F. and Zucca, E. and Illerhaus, G.
Leukemia 36 (7): 1870-1878. July 2022

Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
Maschmeyer, G. and Bullinger, L. and Garcia-Vidal, C. and Herbrecht, R. and Maertens, J. and Menna, P. and Pagano, L. and Thiebaut-Bertrand, A. and Calandra, T.
Leukemia 36 (5): 1215-1226. May 2022

Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9.
Christen, F. and Hablesreiter, R. and Hoyer, K. and Hennch, C. and Maluck-Böttcher, A. and Segler, A. and Madadi, A. and Frick, M. and Bullinger, L. and Briest, F. and Damm, F.
Leukemia 36 (4): 1102-1110. April 2022

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
Damaschin, C. and Goergen, H. and Kreissl, S. and Plütschow, A. and Breywisch, F. and Mathas, S. and Meissner, J. and Sökler, M. and Topp, M.S. and Vucinic, V. and Zimmermann, A. and von Tresckow, B. and Fuchs, M. and Engert, A. and Borchmann, P. and Eichenauer, D.A.
Leukemia 36 (2): 580-582. February 2022

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rücker, F.G. and Du, L. and Luck, T.J. and Benner, A. and Krzykalla, J. and Gathmann, I. and Voso, M.T. and Amadori, S. and Prior, T.W. and Brandwein, J.M. and Appelbaum, F.R. and Medeiros, B.C. and Tallman, M.S. and Savoie, L. and Sierra, J. and Pallaud, C. and Sanz, M.A. and Jansen, J.H. and Niederwieser, D. and Fischer, T. and Ehninger, G. and Heuser, M. and Ganser, A. and Bullinger, L. and Larson, R.A. and Bloomfield, C.D. and Stone, R.M. and Döhner, H. and Thiede, C. and Döhner, K.
Leukemia 36 (1): 90-99. January 2022

2021

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
Lewis, R. and Maurer, H.C. and Singh, N. and Gonzalez-Menendez, I. and Wirth, M. and Schick, M. and Zhang, L. and Isaakidis, K. and Scherger, A.K. and Schulze, V. and Lu, J. and Zenz, T. and Steiger, K. and Rad, R. and Quintanilla-Martinez, L. and Espeli, M. and Balabanian, K. and Keller, U. and Habringer, S.
Leukemia 35 : 2895-2905. October 2021

Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
Rapaport, F. and Neelamraju, Y. and Baslan, T. and Hassane, D. and Gruszczynska, A. and de Massy, M.R. and Farnoud, N. and Haddox, S. and Lee, T. and Medina-Martinez, J. and Sheridan, C. and Thurmond, A. and Becker, M. and Bekiranov, S. and Carroll, M. and Moses Murdock, H. and Valk, P.J.M. and Bullinger, L. and D’Andrea, R. and Lowe, S.W. and Neuberg, D. and Levine, R.L. and Melnick, A. and Garrett-Bakelman, F.E.
Leukemia 35 (9): 2688-2692. September 2021

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Wulf, G.G. and Altmann, B. and Ziepert, M. and D'Amore, F. and Held, G. and Greil, R. and Tournilhac, O. and Relander, T. and Viardot, A. and Wilhelm, M. and Wilhelm, C. and Pezzutto, A. and Zijlstra, J.M. and Van Den Neste, E. and Lugtenburg, P.J. and Doorduijn, J.K. and van Gelder, M. and van Imhoff, G.W. and Zettl, F. and Braulke, F. and Nickelsen, M. and Glass, B. and Rosenwald, A. and Gaulard, P. and Loeffler, M. and Pfreundschuh, M. and Schmitz, N. and Trümper, L.
Leukemia 35 (1): 143-155. January 2021

2020

High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann, R. and Voskanyan, A. and Lauseker, M. and Pfirrmann, M. and Kalmanti, L. and Rinaldetti, S. and Kohlbrenner, K. and Haferlach, C. and Schlegelberger, B. and Fabarius, A. and Seifarth, W. and Spieß, B. and Wuchter, P. and Krause, S. and Kolb, H.J. and Neubauer, A. and Hossfeld, D.K. and Nerl, C. and Gratwohl, A. and Baerlocher, G.M. and Burchert, A. and Brümmendorf, T.H. and Hasford, J. and Hochhaus, A. and Saußele, S. and Baccarani, M.
Leukemia 34 (8): 2074-2086. August 2020

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib/II study.
Rambaldi, A. and Iurlo, A. and Vannucchi, A.M. and Noble, R. and von Bubnoff, N. and Guarini, A. and Martino, B. and Pezzutto, A. and Carli, G. and De Muro, M. and Luciani, S. and McMullin, M.F. and Cambier, N. and Marolleau, J.P. and Mesa, R.A. and Tibes, R. and Pancrazzi, A. and Gesullo, F. and Bettica, P. and Manzoni, S. and Di Tollo, S.
Leukemia 34 (8): 2234-2237. August 2020

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
Agrawal, M. and Schwarz, P. and Giaimo, B.D. and Bedzhov, I. and Corbacioglu, A. and Weber, D. and Gaidzik, V.I. and Jahn, N. and Rücker, F.G. and Schroeder, T. and Kindler, T. and Wattad, M. and Götze, K. and Lübbert, M. and Salwender, H. and Ringhoffer, M. and Lange, E. and Koller, E. and Thol, F. and Heuser, M. and Ganser, A. and Bullinger, L. and Paschka, P. and Döhner, H. and Geiger, H. and Borggrefe, T. and Döhner, K. and Oswald, F.
Leukemia 34 (2): 630-634. February 2020

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).
Meyer, T. and Jahn, N. and Lindner, S. and Röhner, L. and Dolnik, A. and Weber, D. and Scheffold, A. and Köpff, S. and Paschka, P. and Gaidzik, V.I. and Heckl, D. and Wiese, S. and Ebert, B.L. and Döhner, H. and Bullinger, L. and Döhner, K. and Krönke, J.
Leukemia 34 (2): 404-415. February 2020

2019

getITD for FLT3-ITD-based MRD monitoring in AML.
Blätte, T.J. and Schmalbrock, L.K. and Skambraks, S. and Lux, S. and Cocciardi, S. and Dolnik, A. and Döhner, H. and Döhner, K. and Bullinger, L.
Leukemia 33 (10): 2535-2539. October 2019

Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma.
Edginton-White, B. and Cauchy, P. and Assi, S.A. and Hartmann, S. and Riggs, A.G. and Mathas, S. and Cockerill, P.N. and Bonifer, C.
Leukemia 33 (6): 1463-1474. June 2019

Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies.
Çakmak-Görür, N. and Radke, J. and Rhein, S. and Schumann, E. and Willimsky, G. and Heppner, F.L. and Blankenstein, T. and Pezzutto, A.
Leukemia 33 (4): 1039-1043. April 2019

2018

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Döhner, H. and Dolnik, A. and Tang, L. and Seymour, J.F. and Minden, M.D. and Stone, R.M. and Del Castillo, T.B. and Al-Ali, H.K. and Santini, V. and Vyas, P. and Beach, C L. and MacBeth, K.J. and Skikne, B.S. and Songer, S. and Tu, N. and Bullinger, L. and Dombret, H.
Leukemia 32 (12): 2546-2557. December 2018

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
L'Abbate, A. and Tolomeo, D. and Cifola, I. and Severgnini, M. and Turchiano, A. and Augello, B. and Squeo, G. and D'Addabbo, P. and Traversa, D. and Daniele, G. and Lonoce, A. and Pafundi, M. and Carella, M. and Palumbo, O. and Dolnik, A. and Muehlematter, D. and Schoumans, J. and Van Roy, N. and De Bellis, G. and Martinelli, G. and Merla, G. and Bullinger, L. and Haferlach, C. and Storlazzi, C.T.
Leukemia 32 (10): 2152-2166. October 2018

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
Rudat, S. and Pfaus, A. and Cheng, Y.Y. and Holtmann, J. and Ellegast, J.M. and Bühler, C. and Marcantonio, D.D. and Martinez, E. and Göllner, S. and Wickenhauser, C. and Müller-Tidow, C. and Lutz, C. and Bullinger, L. and Milsom, M.D. and Sykes, S.M. and Fröhling, S. and Scholl, C.
Leukemia 32 (10): 2189-2202. October 2018

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis.
Arends, C.M. and Galan-Sousa, J. and Hoyer, K. and Chan, W. and Jäger, M. and Yoshida, K. and Seemann, R. and Noerenberg, D. and Waldhueter, N. and Fleischer-Notter, H. and Christen, F. and Schmitt, C.A. and Dörken, B. and Pelzer, U. and Sinn, M. and Zemojtel, T. and Ogawa, S. and Märdian, S. and Schreiber, A. and Kunitz, A. and Krüger, U. and Bullinger, L. and Mylonas, E. and Frick, M. and Damm, F.
Leukemia 32 (9): 1908-1919. September 2018

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
Schleussner, N. and Merkel, O. and Costanza, M. and Liang, H.C. and Hummel, F. and Romagnani, C. and Durek, P. and Anagnostopoulos, I. and Hummel, M. and Jöhrens, K. and Niedobitek, A. and Griffin, P.R. and Piva, R. and Sczakiel, H.L. and Woessmann, W. and Damm-Welk, C. and Hinze, C. and Stoiber, D. and Gillissen, B. and Turner, S.D. and Kaergel, E. and von Hoff, L. and Grau, M. and Lenz, G. and Dörken, B. and Scheidereit, C. and Kenner, L. and Janz, M. and Mathas, S.
Leukemia 32 (9): 1994-2007. September 2018

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
Paschka, P. and Schlenk, R.F. and Weber, D. and Benner, A. and Bullinger, L. and Heuser, M. and Gaidzik, V.I. and Thol, F. and Agrawal, M. and Teleanu, V. and Lübbert, M. and Fiedler, W. and Radsak, M. and Krauter, J. and Horst, H.A. and Greil, R. and Mayer, K. and Kündgen, A. and Martens, U. and Heil, G. and Salih, H.R. and Hertenstein, B. and Schwänen, C. and Wulf, G. and Lange, E. and Pfreundschuh, M. and Ringhoffer, M. and Girschikofsky, M. and Heinicke, T. and Kraemer, D. and Göhring, G. and Ganser, A. and Döhner, K. and Döhner, H.
Leukemia 32 (7): 1621-1630. July 2018

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.
Mohr, J. and Dash, B.P. and Schnoeder, T.M. and Wolleschak, D. and Herzog, C. and Tubio Santamaria, N. and Weinert, S. and Godavarthy, S. and Zanetti, C. and Naumann, M. and Hartleben, B. and Huber, T.B. and Krause, D.S. and Kähne, T. and Bullinger, L. and Heidel, F.H.
Leukemia 32 (5): 1211-1221. May 2018

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
Gaidzik, V.I. and Weber, D. and Paschka, P. and Kaumanns, A. and Krieger, S. and Corbacioglu, A. and Krönke, J. and Kapp-Schwoerer, S. and Krämer, D. and Horst, H.A. and Schmidt-Wolf, I. and Held, G. and Kündgen, A. and Ringhoffer, M. and Götze, K. and Kindler, T. and Fiedler, W. and Wattad, M. and Schlenk, R.F. and Bullinger, L. and Teleanu, V. and Schlegelberger, B. and Thol, F. and Heuser, M. and Ganser, A. and Döhner, H. and Döhner, K.
Leukemia 32 (1): 30-37. January 2018

2017

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Hehlmann, R. and Lauseker, M. and Saußele, S. and Pfirrmann, M. and Krause, S. and Kolb, H.J. and Neubauer, A. and Hossfeld, D.K. and Nerl, C. and Gratwohl, A. and Baerlocher, G.M. and Heim, D. and Brümmendorf, T.H. and Fabarius, A. and Haferlach, C. and Schlegelberger, B. and Müller, M.C. and Jeromin, S. and Proetel, U. and Kohlbrenner, K. and Voskanyan, A. and Rinaldetti, S. and Seifarth, W. and Spieß, B. and Balleisen, L. and Goebeler, M.C. and Hänel, M. and Ho, A. and Dengler, J. and Falge, C. and Kanz, L. and Kremers, S. and Burchert, A. and Kneba, M. and Stegelmann, F. and Köhne, C.A. and Lindemann, H.W. and Waller, C.F. and Pfreundschuh, M. and Spiekermann, K. and Berdel, W.E. and Müller, L. and Edinger, M. and Mayer, J. and Beelen, D.W. and Bentz, M. and Link, H. and Hertenstein, B. and Fuchs, R. and Wernli, M. and Schlegel, F. and Schlag, R. and de Wit, M. and Trümper, L. and Hebart, H. and Hahn, M. and Thomalla, J. and Scheid, C. and Schafhausen, P. and Verbeek, W. and Eckart, M.J. and Gassmann, W. and Pezzutto, A. and Schenk, M. and Brossart, P. and Geer, T. and Bildat, S. and Schäfer, E. and Hochhaus, A. and Hasford, J.
Leukemia 31 (11): 2398-2406. November 2017

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel, V.N. and Giaimo, B.D. and Schwarz, P. and Soller, K. and Vas, V. and Bartkuhn, M. and Blätte, T.J. and Döhner, K. and Bullinger, L. and Borggrefe, T. and Geiger, H. and Oswald, F.
Leukemia 31 (11): 2491-2502. November 2017

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Young, E. and Noerenberg, D. and Mansouri, L. and Ljungström, V. and Frick, M. and Sutton, L.A. and Blakemore, S.J. and Galan-Sousa, J. and Plevova, K. and Baliakas, P. and Rossi, D. and Clifford, R. and Roos-Weil, D. and Navrkalova, V. and Dörken, B. and Schmitt, C.A. and Smedby, K.E. and Juliusson, G. and Giacopelli, B. and Blachly, J.S. and Belessi, C. and Panagiotidis, P. and Chiorazzi, N. and Davi, F. and Langerak, A.W. and Oscier, D. and Schuh, A. and Gaidano, G. and Ghia, P. and Xu, W. and Fan, L. and Bernard, O.A. and Nguyen-Khac, F. and Rassenti, L. and Li, J. and Kipps, T.J. and Stamatopoulos, K. and Pospisilova, S. and Zenz, T. and Oakes, C.C. and Strefford, J.C. and Rosenquist, R. and Damm, F.
Leukemia 31 (7): 1547-1554. July 2017

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke, J. and Kuchenbauer, F. and Kull, M. and Teleanu, V. and Bullinger, L. and Bunjes, D. and Greiner, A. and Kolmus, S. and Köpff, S. and Schreder, M. and Mügge, L.O. and Straka, C. and Engelhardt, M. and Döhner, H. and Einsele, H. and Bassermann, F. and Bargou, R. and Knop, S. and Langer, C.
Leukemia 31 (6): 1363-1367. June 2017

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol, F. and Klesse, S. and Köhler, L. and Gabdoulline, R. and Kloos, A. and Liebich, A. and Wichmann, M. and Chaturvedi, A. and Fabisch, J. and Gaidzik, V.I. and Paschka, P. and Bullinger, L. and Bug, G. and Serve, H. and Göhring, G. and Schlegelberger, B. and Lübbert, M. and Kirchner, H. and Wattad, M. and Kraemer, D. and Hertenstein, B. and Heil, G. and Fiedler, W. and Krauter, J. and Schlenk, R.F. and Döhner, K. and Döhner, H. and Ganser, A. and Heuser, M.
Leukemia 31 (6): 1286-1295. June 2017

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.
Jahn, N. and Agrawal, M. and Bullinger, L. and Weber, D. and Corbacioglu, A. and Gaidzik, V.I. and Schmalbrock, L. and Thol, F. and Heuser, M. and Krauter, J. and Göhring, G. and Kündgen, A. and Fiedler, W. and Wattad, M. and Held, G. and Köhne, C.H. and Horst, H.A. and Lübbert, M. and Ganser, A. and Schlenk, R.F. and Döhner, H. and Döhner, K. and Paschka, P.
Leukemia 31 (4): 1012-1015. April 2017

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.
Wurster, K.D. and Hummel, F. and Richter, J. and Giefing, M. and Hartmann, S. and Hansmann, M.L. and Kreher, S. and Köchert, K. and Krappmann, D. and Klapper, W. and Hummel, M. and Wenzel, S.S. and Lenz, G. and Janz, M. and Dörken, B. and Siebert, R. and Mathas, S.
Leukemia 31 (3): 602-613. March 2017

2016

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik, V.I. and Teleanu, V. and Papaemmanuil, E. and Weber, D. and Paschka, P. and Hahn, J. and Wallrabenstein, T. and Kolbinger, B. and Köhne, C.H. and Horst, H.A. and Brossart, P. and Held, G. and Kündgen, A. and Ringhoffer, M. and Götze, K. and Rummel, M. and Gerstung, M. and Campbell, P. and Kraus, J.M. and Kestler, H.A. and Thol, F. and Heuser, M. and Schlegelberger, B. and Ganser, A. and Bullinger, L. and Schlenk, R.F. and Döhner, K. and Döhner, H.
Leukemia 30 (11): 2160-2168. November 2016

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
Theis, F. and Corbacioglu, A. and Gaidzik, V.I. and Paschka, P. and Weber, D. and Bullinger, L. and Heuser, M. and Ganser, A. and Thol, F. and Schlegelberger, B. and Göhring, G. and Köhne, C.H. and Germing, U. and Brossart, P. and Horst, H.A. and Haase, D. and Götze, K. and Ringhoffer, M. and Fiedler, W. and Nachbaur, D. and Kindler, T. and Held, G. and Lübbert, M. and Wattad, M. and Salih, H.R. and Krauter, J. and Döhner, H. and Schlenk, R.F. and Döhner, K.
Leukemia 30 (11): 2248-2250. November 2016

GPR56 contributes to the development of acute myeloid leukemia in mice.
Daria, D. and Kirsten, N. and Muranyi, A. and Mulaw, M. and Ihme, S. and Kechter, A. and Hollnagel, M. and Bullinger, L. and Döhner, K. and Döhner, H. and Feuring-Buske, M. and Buske, C.
Leukemia 30 (8): 1734-1741. August 2016

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Arreba-Tutusaus, P. and Mack, T.S. and Bullinger, L. and Schnöder, T.M. and Polanetzki, A. and Weinert, S. and Ballaschk, A. and Wang, Z. and Deshpande, A.J. and Armstrong, S.A. and Döhner, K. and Fischer, T. and Heidel, F.H.
Leukemia 30 (5): 1220-1225. May 2016

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial.
Ferrero, S. and Pastore, A. and Scholz, C.W. and Forstpointner, R. and Pezzutto, A. and Bergmann, L. and Truemper, L. and Finke, J. and Keller, U. and Ghione, P. and Passera, R. and Hiddemann, W. and Weigert, O. and Unterhalt, M. and Dreyling, M.
Leukemia 30 (4): 984-987. April 2016

Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.
Nowek, K. and Sun, S.M. and Dijkstra, M.K. and Bullinger, L. and Döhner, H. and Erkeland, S.J. and Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 30 (2): 303-9. February 2016

Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.
Nowek, K. and Sun, S.M. and Bullinger, L. and Bindels, E.M.J. and Exalto, C. and Dijkstra, M.K. and van Lom, K. and Döhner, H. and Erkeland, S.J. and Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 30 (1): 229-37. January 2016

2015

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey.
Zeiser, R. and Burchert, A. and Lengerke, C. and Verbeek, M. and Maas-Bauer, K. and Metzelder, S.K. and Spoerl, S. and Ditschkowski, M. and Ecsedi, M. and Sockel, K. and Ayuk, F. and Ajib, S. and de Fontbrune, F.S. and Na, I.K. and Penter, L. and Holtick, U. and Wolf, D. and Schuler, E. and Meyer, E. and Apostolova, P. and Bertz, H. and Marks, R. and Lübbert, M. and Wäsch, R. and Scheid, C. and Stölzel, F. and Ordemann, R. and Bug, G. and Kobbe, G. and Negrin, R. and Brune, M. and Spyridonidis, A. and Schmitt-Gräff, A. and van der Velden, W. and Huls, G. and Mielke, S. and Grigoleit, G.U. and Kuball, J. and Flynn, R. and Ihorst, G. and Du, J. and Blazar, B.R. and Arnold, R. and Kröger, N. and Passweg, J. and Halter, J. and Socie, G. and Beelen, D. and Peschel, C. and Neubauer, A. and Finke, J. and Duyster, J. and von Bubnoff, N.
Leukemia 29 (10): 2062-2068. October 2015

Cellular origin of prognostic chromosomal aberrations in AML patients.
Mora-Jensen, H. and Jendholm, J. and Rapin, N. and Andersen, M.K. and Roug, A.S. and Bagger, F.O. and Bullinger, L. and Winther, O. and Borregaard, N. and Porse, B.T. and Theilgaard-Mönch, K.
Leukemia 29 (8): 1785-9. August 2015

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
Pfeifer, M. and Zheng, B. and Erdmann, T. and Koeppen, H. and McCord, R. and Grau, M. and Staiger, A. and Chai, A. and Sandmann, T. and Madle, H. and Doerken, B. and Chu, Y.W. and Chen, A.I. and Lebovic, D. and Salles, G.A. and Czuczman, M.S. and Palanca-Wessels, M.C. and Press, O.W. and Advani, R. and Morschhauser, F. and Cheson, B.D. and Lenz, P. and Ott, G. and Polson, A.G. and Mundt, K.E. and Lenz, G.
Leukemia 29 (7): 1578-1586. July 2015

The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells.
Ullrich, K. and Blumenthal-Barby, F. and Lamprecht, B. and Koechert, K. and Lenze, D. and Hummel, M. and Mathas, S. and Doerken, B. and Janz, M.
Leukemia 29 (5): 1213-1218. May 2015

TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
Willer, A. and Jakobsen, J.S. and Ohlsson, E. and Rapin, N. and Waage, J. and Billing, M. and Bullinger, L. and Karlsson, S. and Porse, B.T.
Leukemia 29 (5): 1018-1031. May 2015

2014

Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A.
Auer, F. and Rueschendorf, F. and Gombert, M. and Husemann, P. and Ginzel, S. and Izraeli, S. and Harit, M. and Weintraub, M. and Weinstein, O.Y. and Lerer, I. and Stepensky, P. and Borkhardt, A. and Hauer, J.
Leukemia 28 (5): 1136-1138. May 2014

2013

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Wenzel, S.S. and Grau, M. and Mavis, C. and Hailfinger, S. and Wolf, A. and Madle, H. and Deeb, G. and Doerken, B. and Thome, M. and Lenz, P. and Dirnhofer, S. and Hernandez-Ilizaliturri, F.J. and Tzankov, A. and Lenz, G.
Leukemia 27 (6): 1381-1390. June 2013

Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or Imatinib.
Kim, T.D. and Rea, D. and Schwarz, M. and Grille, P. and Nicolini, F.E. and Rosti, G. and Levato, L. and Giles, F.J. and Dombret, H. and Mirault, T. and Labussiere, H. and Lindhorst, R. and Haverkamp, W. and Buschmann, I. and Doerken, B. and le Coutre, P.D.
Leukemia 27 (6): 1316-1321. 5 April 2013

2012

Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.
Schwarzer, R. and Doerken, B. and Jundt, F.
Leukemia 26 (4): 806-813. April 2012

NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia.
Terwey, T.H. and Vega-Ruiz, A. and Hemmati, P.G. and Martus, P. and Dietz, E. and le Coutre, P. and Massenkeil, G. and Doerken, B. and Arnold, R.
Leukemia 26 (3): 536-542. March 2012

2008

Notch inhibition blocks multiple myeloma cell-induced osteoclast activation.
Schwarzer, R. and Kaiser, M. and Acikgoez, O. and Heider, U. and Mathas, S. and Preissner, R. and Sezer, O. and Doerken, B. and Jundt, F.
Leukemia 22 (12): 2273-2277. December 2008

Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma.
Jundt, F. and Acikgoez, O. and Kwon, S.H. and Schwarzer, R. and Anagnostopoulos, I. and Wiesner, B. and Mathas, S. and Hummel, M. and Stein, H. and Reichardt, H.M. and Doerken, B.
Leukemia 22 (8): 1587-1594. August 2008

2007

Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells.
Janz, M. and Stuehmer, T. and Vassilev, L.T. and Bargou, R.C.
Leukemia 21 (4): 772-779. April 2007

2006

High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis.
Steiner, K. and Graf, M. and Hecht, K. and Reif, S. and Rossbacher, L. and Pfister, K. and Kolb, H.J. and Schmetzer, H.M. and Multhoff, G.
Leukemia 20 (11): 2076-2079. November 2006

Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
Einsiedel, H.G. and Kawan, L. and Eckert, C. and Witt, O. and Fichtner, I. and Henze, G. and Seeger, K.
Leukemia 20 (8): 1435-1436. August 2006

2005

Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Schmelz, K. and Sattler, N. and Wagner, M. and Luebbert, M. and Doerken, B. and Tamm, I.
Leukemia 19 : 103-111. 1 January 2005

2004

Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient.
Subklewe, M. and Nagy, M. and Schoch, C. and Jenisch, S. and Siebert, R. and Gesk, S. and Neuhaus, P. and Doerken, B. and Schmidt, C.A.
Leukemia 18 (12): 2050-2053. 7 October 2004

A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
Hoenemann, D. and Kufer, P. and Rimpler, M.M. and Chatterjee, M. and Friedl, S. and Riecher, F. and Bommert, K. and Doerken, B. and Bargou, R.C.
Leukemia 18 (3): 636-644. 1 January 2004

PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.
Lentzsch, S. and Chatterjee, M. and Gries, M. and Bommert, K. and Gollasch, H. and Doerken, B. and Bargou, R.C.
Leukemia 18 (11): 1883-1890. 1 January 2004

2003

Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk, R.F. and Benner, A. and Hartmann, F. and del Valle, F. and Weber, C. and Pralle, H. and Fischer, J.T. and Gunzer, U. and Pezzutto, A. and Weber, W. and Grimminger, W. and Preiss, J. and Hensel, M. and Froehling, S. and Doehner, K. and Haas, R. and Doehner, H.
Leukemia 17 (8): 1521-1528. 1 August 2003

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Loeffler, A. and Gruen, M. and Wuchter, C. and Schriever, F. and Kufer, P. and Dreier, T. and Hanakam, F. and Baeuerle, P.A. and Bommert, K. and Karawajew, L. and Doerken, B. and Bargou, R.C.
Leukemia 17 (5): 900-909. May 2003

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Lentzsch, S. and LeBlanc, R. and Podar, K. and Davies, F. and Lin, B. and Hideshima, T. and Catley, L. and Stirling, D.I. and Anderson, K.C.
Leukemia 17 : 41-44. 1 January 2003

2002

Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy.
Kern, W. and Haferlach, T. and Schnittger, S. and Ludwig, W.D. and Hiddemann, W. and Schoch, C.
Leukemia 16, 10 : 2084-2091. 1 October 2002

Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases.
Borkhardt, A. and Wuchter, C. and Viehmann, S. and Pils, S. and Teigler-Schlegel, A. and Stanulla, M. and Zimmermann, M. and Ludwig, W.D. and Janka-Schaub, G. and Schrappe, M. and Harbott, J.
Leukemia 16, 9 : 1685-1690. 1 September 2002

Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet, A.G. and Sturm, I. and Wieder, T. and Essmann, F. and Bosanquet, M.I. and Head, F.J. and Doerken, B. and Daniel, P.T.
Leukemia 16 (6): 1035-1044. June 2002

2001

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Gupta, D. and Treon, S.P. and Shima, Y. and Hideshima, T. and Podar, K. and Tai, Y.T. and Lin, B. and Lentzsch, S. and Davies, F.E. and Chauhan, D. and Schlossman, R.L. and Richardson, P. and Ralph, P. and Wu, L. and Payvandi, F. and Muller, G. and Stirling, D.I. and Anderson, K.C.
Leukemia 15 : 1950-1961. 1 December 2001

Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts.
Wieder, T. and Prokop, A. and Bagci, B. and Essmann, F. and Bernicke, D. and Schulze-Osthoff, K. and Doerken, B. and Schmalz, H.G. and Daniel, P.T. and Henze, G.
Leukemia 15 (11): 1735-1742. 1 November 2001

The kiss of death: promises and failures of death receptors and ligands in cancer therapy.
Daniel, P.T. and Wieder, T. and Sturm, I. and Schulze-Osthoff, K.
Leukemia 15 (7): 1022-1032. 1 July 2001

Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation.
Cai, Z. and Lin, M. and Wuchter, C. and Ruppert, V. and Doerken, B. and Ludwig, W.D. and Karawajew, L.
Leukemia 15 : 567-574. 1 January 2001

In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappaB activity.
Wuchter, C. and Krappmann, D. and Cai, Z. and Ruppert, V. and Scheidereit, C. and Doerken, B. and Ludwig, W.D. and Karawajew, L.
Leukemia 15 (6): 921-928. 1 January 2001

2000

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster.
Schrappe, M. and Reiter, A. and Zimmermann, M. and Harbott, J. and Ludwig, W.D. and Henze, G. and Gadner, H. and Odenwald, E. and Riehm, H.
Leukemia 14 (12): 2205-2222. 1 December 2000

Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo.
Prokop, A. and Wieder, T. and Sturm, I. and Essmann, F. and Seeger, K. and Wuchter, C. and Ludwig, W.D. and Henze, G. and Doerken, B. and Daniel, P.T.
Leukemia 14 : 1606-1613. 1 September 2000

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Lengfelder, E. and Reichert, A. and Schoch, C. and Haase, D. and Haferlach, T. and Loeffler, H. and Staib, P. and Heyll, A. and Seifarth, W. and Saussele, S. and Fonatsch, C. and Gassmann, W. and Ludwig, W.D. and Hochhaus, A. and Beelen, D. and Aul, C. and Sauerland, M.C. and Heinecke, A. and Hehlmann, R. and Woermann, B. and Hiddemann, W. and Buechner, T.
Leukemia 14 : 1362-1370. 1 August 2000

Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1.
Wuchter, C. and Harbott, J. and Schoch, C. and Schnittger, S. and Borkhardt, A. and Karawajew, L. and Ratei, R. and Ruppert, V. and Haferlach, T. and Creutzig, U. and Doerken, B. and Ludwig, W.D.
Leukemia 14 : 1232-1238. 1 July 2000

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.
Kordes, U. and Krappmann, D. and Heissmeyer, V. and Ludwig, W.D. and Scheidereit, C.
Leukemia 14 (3): 399-402. March 2000

Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life.
Stanulla, M. and Kasper, B. and Schrappe, M. and Viehmann, S. and Harbott, J. and Ludwig, W.D. and Welte, K.
Leukemia 14 : 337-338. 1 February 2000

Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients.
Bohlander, S.K. and Muschinsky, V. and Schrader, K. and Siebert, R. and Schlegelberger, B. and Harder, L. and Schemmel, V. and Fonatsch, C. and Ludwig, W.D. and Hiddemann, W. and Dreyling, M.H.
Leukemia 14 : 93-99. 1 January 2000

1999

Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Wuchter, C. and Karawajew, L. and Ruppert, V. and Buechner, T. and Schoch, C. and Hafelach, T. and Ratei, R. and Doerken, B. and Ludwig, W.D.
Leukemia 13 : 1943-1953. 1 December 1999

First non-imported HTLV-1 positive adult T cell leukemia/lymphoma (ATLL) in Germany.
Reinhardt, P. and Maschmeyer, G. and Schulze, G. and Fleischer, C. and Ellerbrok, H. and Schlegelberger, B. and Stein, H. and Pauli, G. and Ludwig, W.D.
Leukemia 13 : 1296-1297. 1 August 1999

Immunophenotypic and immunogenotypic characteristics of TCR gammadelta+ T cell acute lymphoblastic leukemia.
Langerak, A.W. and Wolvers-Tettero, I.L. and van den Beemd, M.W.M. and van Wering, E.R. and Ludwig, W.D. and Haehlen, K. and Necker, A. and van Dongen, J.J.M.
Leukemia 13 : 206-214. 1 February 1999

1998

High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia.
Rieder, H. and Bonwetsch, C. and Janssen, L.A.J. and Maurer, J. and Janssen, J.W.G. and Schwartz, S. and Ludwig, W.D. and Gassmann, W. and Bartram, C.R. and Thiel, E. and Loeffler, H. and Gokbuget, N. and Hoelzer, D. and Fonatsch, C.
Leukemia 12 : 1473-1481. 1 September 1998

Expression and regulation of c-kit receptor and response to stem cell factor in childhood malignant T-lymphoblastic cells.
Tomeczkowski, J. and Frick, D. and Schwinzer, B. and Wittner, N. and Ludwig, W.D. and Reiter, A. and Welte, K. and Sykora, K.W.
Leukemia 12 : 1221-1229. 1 August 1998

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern, W. and Aul, C. and Maschmeyer, G. and Schoenrock-Nabulsi, R. and Ludwig, W.D. and Bartholomaeus, A. and Bettelheim, P. and Woermann, B. and Buechner, T. and Hiddemann, W.
Leukemia 12 : 1049-1055. 1 July 1998

Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials.
Dordelmann, M. and Schrappe, M. and Reiter, A. and Zimmermann, M. and Graf, N. and Schott, G. and Lampert, F. and Harbott, J. and Niemeyer, C. and Ritter, J. and Dorffel, W. and Nessler, G. and Kuhl, J. and Riehm, H.
Leukemia 12 : 645-651. 1 May 1998

Detection of hyperdiploid karyotypes (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) using fluorescence in situ hybridization (FISH).
Ritterbach, J. and Hiddemann, W. and Beck, J.D. and Schrappe, M. and Janka-Schaub, G. and Ludwig, W.D. and Harbott, J. and Lampert, F.
Leukemia 12 : 427-433. 1 March 1998

1997

Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells.
Karawajew, L. and Wuchter, C. and Ruppert, V. and Drexler, H. and Gruss, H.J. and Doerken, B. and Ludwig, W.D.
Leukemia 11 : 1245-1252. 1 January 1997

1996

Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.
Creutzig, U. and Ritter, J. and Vormoor, J. and Ludwig, W.D. and Niemeyer, C. and Reinisch, I. and Stollmann-Gibbels, B. and Zimmermann, M. and Harbott, J.
Leukemia 10 (11): 1677-1686. 1 November 1996

Classification of acute leukemias: reply from EGIL to Dr van Dongen.
Bene, M.C. and Castoldi, G. and Knapp, W. and Ludwig, W.D. and Matutes, E. and Orfao, A. and van't Veer, M.B.
Leukemia 10 : 1363-1364. 1 January 1996

Effects of FLT3 ligand on human leukemia cells. I. proliferative response of myeloid leukemia cells.
Dehmel, U. and Zaborski, M. and Meierhoff, G. and Rosnet, O. and Birnbaum, D. and Ludwig, W.D. and Quentmeier, H. and Drexler, H.G.
Leukemia 10 (2): 261-270. 1 January 1996

Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells.
Quentmeier, H. and Zaborski, M. and Graf, G. and Ludwig, W.D. and Drexler, H.G.
Leukemia 10 : 297-310. 1 January 1996

Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies.
Rothe, G. and Schmitz, G. and Adorf, D. and Barlage, S. and Gramatzki, M. and Hanenberg, H. and Hoeffkes, H.G. and Janossy, G. and Knuechel, R. and Ludwig, W.D. and Nebe, T. and Nerl, C. and Orfao, A. and Serke, S. and Sonnen, R. and Tichelli, A. and Woermann, B.
Leukemia 10 (5): 877-895. 1 January 1996

Incidence and clinical outcome of children with bcr/abl positive acute lymphoblastic leukemia (ALL): a prospective rt PCR study based on 673 patients enrolled in the German Pediatric Multicenter therapy trials ALL BFM 90 and coALL 05 92.
Schlieben, S. and Borkhardt, A. and Reinisch, I. and Ritterbach, J. and Janssen, J.W. and Ratei, R. and Schrappe, M. and Repp, R. and Zimmermann, M. and Kabisch, H. and Janka-Schaub, G. and Bartram, C.R. and Ludwig, W.D. and Riehm, H. and Lampert, F. and Harbott, J.
Leukemia 10 : 957-963. 1 January 1996

1995

Proposals for the immunological classification of acute leukemias.
Bene, M.C. and Castoldi, G. and Knapp, W. and Ludwig, W.D. and Matutes, E. and Orfao, A. and Vantveer, M.B.
Leukemia 9 (10): 1783-1786. 1 October 1995

Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia.
Meckenstock, G. and Heyll, A. and Schneider, E.M. and Hildebrandt, B. and Runde, V. and Aul, C. and Bartram, C.R. and Ludwig, W.D. and Schneider, W.
Leukemia 9 : 260-264. 1 January 1995

1994

Mechanisms of p53 alteration in acute leukemias.
Schottelius, A. and Brennscheidt, U. and Ludwig, W.D. and Mertelsmann, R.H. and Herrmann, F. and Lubbert, M.
Leukemia 8 : 1673-1681. 1 October 1994

Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26).
Fonatsch, C. and Gudat, H. and Lengfelder, E. and Wandt, H. and Silling-Engelhardt, G. and Ludwig, W.D. and Thiel, E. and Freund, M. and Bodenstein, H. and Schwieder, G. and Gruenelsen, A. and Aul, C. and Schnittger, S. and Rieder, H. and Haase, D. and Hild, F.
Leukemia 8 (8): 1318-1326. 1 August 1994

Essential role of c-myc in ara-C-induced differentiation of human erythroleukemia cells.
Baker, S.J. and Pawlita, M. and Leutz, A. and Hoelzer, D.
Leukemia 8 (8): 1309-1317. August 1994

Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11).
Griesinger, F. and Elfers, H. and Ludwig, W.D. and Falk, M. and Rieder, H. and Harbott, J. and Lampert, F. and Heinze, B. and Hoelzer, D. and Thiel, E. and Riehm, H. and Woermann, B. and Fonatsch, C. and Hiddemann, W.
Leukemia 8 : 542-548. 1 January 1994

APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice.
Luecking-Famira, K.M. and Daniel, P.T. and Moeller, P. and Krammer, P.H. and Debatin, K.M.
Leukemia 8 : 1825-1833. 1 January 1994

Ras point mutations occur in acute myeloid leukemia with illegitimate T-cell receptor delta gene rearrangement.
Schmidt, C.A. and Przybylski, G. and Vogel, D. and Ludwig, W.D. and Oettle, H. and Neubauer, A. and Siegert, W.
Leukemia 8 : 102-105. 1 January 1994

Characterization of the monocyte-specific esterase (MSE) gene.
Uphoff, C.C. and Hu, Z.B. and Gignac, S.M. and Ma, W. and Rainey, F.A. and Kreutz, M. and Ludwig, W.D. and Drexler, H.G.
Leukemia 8 : 1510-1526. 1 January 1994

t(5;14)(q33-34;q11), a new recurring cytogenetic abnormality in childhood acute leukemia.
Whitlock, J.A. and Raimondi, S.C. and Harbott, J. and Morris, S.W. and McCurley, T.L. and Hansen-Hagge, T.E. and Ludwig, W.D. and Weimann, G. and Bartram, C.R.
Leukemia 8 : 1539-1543. 1 January 1994

Timing of peripheral blood progenitor cell (PBPC) collections during recovery from chemotherapy supported by haematopoietic growth factor.
van Hoef, M.E. and Baumann, I. and Lange, C. and De Wynter, E.A. and Testa, N.G. and Howell, A.
Leukemia 8 : 2020-2021. 1 January 1994

1993

Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance.
Drexler, H.G. and Thiel, E. and Ludwig, W.D.
Leukemia 7 (4): 489-498. 1 April 1993

tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease.
Breit, T.M. and Beishuizen, A. and Ludwig, W.D. and Mol, E.J. and Adriaansen, H.J. and van Wering, E.R. and van Dongen, J.J.
Leukemia 7 : 2004-2011. 1 January 1993

Terminal deoxynucleotidyl transferase (TdT) expression in acute myeloid leukemia.
Drexler, H.G. and Sperling, C. and Ludwig, W.D.
Leukemia 7 : 1142-1150. 1 January 1993

Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84).
Hoelzer, D. and Thiel, E. and Ludwig, W.D. and Loeffler, H. and Buechner, T. and Freund, M. and Heil, G. and Hiddemann, W. and Maschmeyer, G. and Voelkers, B. and Goekbuget, N. and Aydemir, U.
Leukemia 7 Suppl. 2 : S130-S134. 1 January 1993

Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cytogenetic and polymerase chain reaction analyses.
Izraeli, S. and Janssen, J.W. and Haas, O.A. and Harbott, J. and Brok Simoni, F. and Walther, J.U. and Kovar, H. and Henn, T. and Ludwig, W.D. and Reiter, A. and Rechavi, G. and Bartram, C.R. and Gadner, H. and Lion, T.
Leukemia 7 : 671-678. 1 January 1993

Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia.
Izraeli, S. and Henn, T. and Strobl, H. and Ludwig, W.D. and Kovar, H. and Haas, O.A. and Harbott, J. and Bartram, C.R. and Gadner, H. and Lion, T.
Leukemia 7 : 2054-2056. 1 January 1993

SIL-TAL1 deletion in T-cell acute lymphoblastic leukemia.
Janssen, J.W. and Ludwig, W.D. and Sterry, W. and Bartram, C.R.
Leukemia 7 : 1204-1210. 1 January 1993

Translocation t(1;22) mimicking t(1;19) in a child with acute lymphoblastic leukemia as revealed by chromosome painting.
Rieder, H. and Kolbus, U. and Koop, U. and Ludwig, W.D. and Stollmann-Gibbels, B. and Fonatsch, C.
Leukemia 7 : 1663-1666. 1 January 1993

1992

Combined effect of very early intensification and prolonged post- remission chemotherapy in patients with AML.
Buechner, T. and Hiddemann, W. and Schaefer, U.W. and Loeffler, H. and Maschmeyer, G. and Ludwig, W.D. and Aul, C. and Lathan, B. and Heinecke, A.
Leukemia 6 Suppl. 4 : 68-70. 1 January 1992

Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.
Buechner, T. and Hiddemann, W. and Woermann, B. and Loeffler, H. and Maschmeyer, G. and Hossfeld, D. and Ludwig, W.D. and Nowrousian, M. and Aul, C. and Schaefer, U.W.
Leukemia 6 Suppl 2 : 68-71. 1 January 1992

The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group.
Hoelzer, D. and Thiel, E. and Ludwig, W.D. and Loeffler, H. and Buechner, T. and Freund, M. and Heil, G. and Hiddemann, W. and Maschmeyer, G. and Voelkers, B. and Aydemir, U.
Leukemia 6 (Suppl. 2): 175-177. 1992